Monodisperse and Nanometric-Sized Calcium Carbonate Particles Synthesis Optimization

Research progress of calcium carbonate nanomaterials in cancer therapy: challenge and opportunity

Cancer has keeping the main threat to the health of human being. Its overall survival rate has shown rare substantial progress in spite of the improving diagnostic and treatment techniques for cancer in recent years. Indeed, such classic strategies for malignant tumor as surgery, radiation and chemotherapy have been developed and bring more hope to the patients, but still been accompanied by certain limitations, which include the challenge of managing large wound sizes, systemic toxic side effects, and harmful to the healthy tissues caused by imprecise alignment with tumors in radiotherapy. Furthermore, immunotherapy exhibits a limited therapeutic effect in advanced tumors which is reported only up to 25%-30%. The combination of nanomaterials and cancer treatment offers new hope for cancer patients, demonstrating strong potential in the field of medical research. Among the extensively utilized nanomaterials, calcium carbonate nanomaterials (CCNM) exhibit a broad spectrum of biomedical applications due to their abundant availability, cost-effectiveness, and exceptional safety profile. CCNM have the potential to elevate intracellular Ca2+ levels in tumor cells, trigger the mitochondrial damage and ultimately lead to tumor cell death. Moreover, compared with other types of nanomaterials, CCNM exhibit remarkable advantages as delivery systems owing to their high loading capacity, biocompatibility and biodegradability. The purpose of this review is to provide an overview of CCNM synthesis, focusing on summarizing its diverse roles in cancer treatment and the benefits and challenges associated with CCNM in cancer therapy. Hoping to present the significance of CCNM as for the clinical application, and summarize information for the design of CCNM and other types of nanomaterials in the future.

In vitro antioxidant activity of alginate nanoparticles encapsulating the aqueous extract of Coccinia grandis L

Bioactive compounds in medicinal plants are more susceptible to preventing oxidative stress. Encapsulation of herbal extracts has empowered the properties and characteristics of bioactive compounds. Nanoencapsulation allows the enhancement of the stability of extracts and targeted drug delivery. The present study aims to determine the antioxidant activity of alginate nanoparticles encapsulating the aqueous extract of Coccinia grandis L. (Family: Cucurbitaceae). The aqueous extract of C. grandis (AqCG) was prepared by using ultrasonication (40 °C, 20 min, 40 kHz) followed by refluxing (2½ h). The prepared AqCG (1-5 mg/mL) encapsulated alginate nanoparticles were synthesized by ionic gelation with the addition of extracts and CaCl2. Characterization of nanoparticles was performed via encapsulation efficiency (EE%), loading capacity (LC%), particle size (PS), scanning electron microscopy (SEM), zeta potential and Fourier transform infrared (FTIR) spectroscopy analysis. The antioxidant activity of the nanoparticles was evaluated in vitro by the ferric reducing antioxidant (FRAP) assay, 2,2-di-phenyl-1-picrylhydrazyl (DPPH) radical scavenging assay and 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical scavenging assay. One-way analysis of variance (ANOVA) followed by Tukey's posthoc test was used to analyze the data. Maximum LC% (3.07 ± 0.11) and average particle size (71 nm from SEM) were obtained for alginate nanoparticles encapsulated at 4 mg/mL extract concentration. The IC50 values for DPPH, ABTS, and FRAP were 6.49 ± 0.10 mg/mL, 0.24 ± 0.01 mg/mL, and 20.63 ± 0.28 mg Trolox equivalent/g of extract respectively for alginate nanoparticles encapsulating the AqCG. Nanoparticles have shown a significant difference in IC50 values compared to Trolox (p < 0.05). The successful encapsulation of the AqCG in the alginate matrix was evidenced by FTIR and SEM analysis. Encapsulation contributed to enhancing the antioxidant activity in terms of ABTS assay when compared to the AqCG. However, in vitro release and stability studies are warranted to facilitate the development of a commercially viable nanonutraceutical using alginate nanoparticles encapsulating the AqCG.

pH-Responsible Doxorubicin-Loaded Fe3O4@CaCO3 Nanocomposites for Cancer Treatment

A magnetic nanocomposite (MNC) is an integrated nanoplatform that combines a set of functions of two types of materials. A successful combination can give rise to a completely new material with unique physical, chemical, and biological properties. The magnetic core of MNC provides the possibility of magnetic resonance or magnetic particle imaging, magnetic field-influenced targeted delivery, hyperthermia, and other outstanding applications. Recently, MNC gained attention for external magnetic field-guided specific delivery to cancer tissue. Further, drug loading enhancement, construction stability, and biocompatibility improvement may lead to high progress in the area. Herein, the novel method for nanoscale Fe3O4@CaCO3 composites synthesis was proposed. For the procedure, oleic acid-modified Fe3O4 nanoparticles were coated with porous CaCO3 using an ion coprecipitation technique. PEG-2000, Tween 20, and DMEM cell media was successfully used as a stabilization agent and template for Fe3O4@CaCO3 synthesis. Transmission electron microscopy (TEM), Fourier transform infrared (FTIR) spectroscopy, and dynamic light scattering (DLS) data were used for the Fe3O4@CaCO3 MNC’s characterization. To improve the nanocomposite properties, the concentration of the magnetic core was varied, yielding optimal size, polydispersity, and aggregation ability. The resulting Fe3O4@CaCO3 had a size of 135 nm with narrow size distributions, which is suitable for biomedical applications. The stability experiment in various pH, cell media, and fetal bovine serum was also evaluated. The material showed low cytotoxicity and high biocompatibility. An excellent anticancer drug doxorubicin (DOX) loading of up to 1900 µg/mg (DOX/MNC) was demonstrated. The Fe3O4@CaCO3/DOX displayed high stability at neutral pH and efficient acid-responsive drug release. The series of DOX-loaded Fe3O4@CaCO3 MNCs indicated effective inhibition of Hela and MCF-7 cell lines, and the IC 50 values were calculated. Moreover, 1.5 μg of the DOX-loaded Fe3O4@CaCO3 nanocomposite is sufficient to inhibit 50% of Hela cells, which shows a high prospect for cancer treatment. The stability experiments for DOX-loaded Fe3O4@CaCO3 in human serum albumin solution indicated the drug release due to the formation of a protein corona. The presented experiment showed the “pitfalls” of DOX-loaded nanocomposites and provided step-by-step guidance on efficient, smart, anticancer nanoconstruction fabrication. Thus, the Fe3O4@CaCO3 nanoplatform exhibits good performance in the cancer treatment area.